- Conditions
- HIV Infections
- Interventions
- Lamivudine/Zidovudine, Nelfinavir mesylate, Aldesleukin
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 398 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • San Francisco, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 169–192
of 1,283
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Brain Neoplasm, Glioblastoma, Glioma, Pituitary Neoplasm
- Interventions
- Not listed
- Lead sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
- NIH
- Eligibility
- Not listed
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1979 – 2005
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Rheumatoid Arthritis (RA)
- Interventions
- ABBV-154, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 473 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 101
- States / cities
- Phoenix, Arizona • Jonesboro, Arkansas • Fullerton, California + 89 more
- Conditions
- Breast Cancer
- Interventions
- fulvestrant, tamoxifen citrate, conventional surgery, neoadjuvant therapy
- Drug · Procedure
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Kidney Cancer, Melanoma (Skin), Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- aldesleukin, recombinant interferon alfa, therapeutic tumor infiltrating lymphocytes, cimetidine
- Biological · Drug
- Lead sponsor
- Hoag Memorial Hospital Presbyterian
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2000
- U.S. locations
- 1
- States / cities
- Newport Beach, California
- Conditions
- Craniopharyngioma, Child
- Interventions
- Tumor and Blood Specimens
- Procedure
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 30 Days to 21 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Atherosclerosis
- Interventions
- Polyarginine, Vein soak treated with Lactated Ringers Solution
- Drug
- Lead sponsor
- St. Luke's Hospital, Chesterfield, Missouri
- Other
- Eligibility
- 25 Years to 95 Years
- Enrollment
- 540 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Chesterfield, Missouri
- Conditions
- Crohn's Disease
- Interventions
- Upadacitinib, Placebo for Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 526 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 119
- States / cities
- Mobile, Alabama • Chandler, Arizona • Scottsdale, Arizona + 93 more
- Conditions
- Sarcoma
- Interventions
- MRI
- Diagnostic Test
- Lead sponsor
- Andrew Frankart
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Cincinnati, Ohio
- Conditions
- Herpes Zoster, Herpes Zoster Vaccine
- Interventions
- Herpes Zoster vaccine GSK 1437173A, Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 865 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 3
- States / cities
- Golden, Colorado • Wichita, Kansas • Columbia, Maryland
- Conditions
- Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage III Lung Cancer
- Interventions
- Biospecimen Collection, Carboplatin, Computed Tomography, Fludeoxyglucose F-18, Nab-paclitaxel, Pembrolizumab, Pemetrexed, Positron Emission Tomography, Radiation Therapy, [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scan, Ipilimumab, Nivolumab, Cemiplimab, Atezolizumab
- Procedure · Drug · Other + 2 more
- Lead sponsor
- Vanderbilt-Ingram Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Atopic Dermatitis
- Interventions
- GBR 830, Placebo
- Biological
- Lead sponsor
- Ichnos Sciences SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 12
- States / cities
- Rogers, Arkansas • Los Angeles, California • San Diego, California + 9 more
- Conditions
- Advanced Solid Tumor, Recurrent Endometrial Cancer, Metastatic Cancer
- Interventions
- ART0380
- Drug
- Lead sponsor
- Artios Pharma Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 5 more
- Conditions
- Crohn's Disease
- Interventions
- Upadacitinib
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2034
- U.S. locations
- 12
- States / cities
- Oakland, California • Palo Alto, California • Aurora, Colorado + 9 more
- Conditions
- Obesity
- Interventions
- obesity
- Other
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Infections, Meningococcal
- Interventions
- rMenB+OMV NZ vaccine, Meningococcal Groups A, C, W and Y Conjugate Vaccine (MenACWY), Placebo, MenABCWY-1, MenABCWY-2, MenABCWY-3
- Combination Product · Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 3,657 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2022
- U.S. locations
- 64
- States / cities
- Chandler, Arizona • Glendale, Arizona • Jonesboro, Arkansas + 51 more
- Conditions
- Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, Obesity
- Interventions
- Etanercept Optimal dosing
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 2 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Depression, Hypertension, Hypercholesterolemia
- Interventions
- Cognitive behavioral therapy
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- Viagenpumatucel-L, Nivolumab, Pembrolizumab, Pemetrexed
- Biological · Drug
- Lead sponsor
- Heat Biologics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 16
- States / cities
- Tucson, Arizona • La Jolla, California • Boca Raton, Florida + 13 more
- Conditions
- Plaque Psoriasis
- Interventions
- Risankizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Hot Springs, Arkansas • North Little Rock, Arkansas + 16 more
- Conditions
- Solid Tumor, Adult, Solid Tumor Cancer
- Interventions
- DF6215, pembrolizumab, KEYTRUDA®
- Drug
- Lead sponsor
- Dragonfly Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Orange, California • San Diego, California + 5 more
- Conditions
- Autoimmune Diseases of the Nervous System, Multiple Sclerosis, Secondary Progressive Multiple Sclerosis, Disease Progression, Brain Atrophy
- Interventions
- Tcelna, Placebo
- Biological
- Lead sponsor
- Opexa Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Berkeley, California + 28 more
- Conditions
- Pulmonary Emphysema, Chronic Obstructive Pulmonary Disease
- Interventions
- Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel
- Drug
- Lead sponsor
- Aeris Therapeutics
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 8
- States / cities
- Phoenix, Arizona • Iowa City, Iowa • Topeka, Kansas + 5 more
- Conditions
- Poliomyelitis, Diphtheria, Haemophilus Influenzae Type b, Tetanus, Acellular Pertussis, Hepatitis B
- Interventions
- Infanrix hexa, Pediarix, ActHIB, Pentacel, Engerix-B, Infanrix, Hiberix, Prevnar13, Rotarix
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 6 Weeks to 12 Weeks
- Enrollment
- 585 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 43
- States / cities
- Tucson, Arizona • Fayetteville, Arkansas • Anaheim, California + 38 more